OakChart

IRulya Therapeutics Inc

IRLAHealthcare·Biotechnology·USA·Small·NASD·Nov 12 • 11:58 AM ET

39.95+1.62 (4.23%)
2026-11-12 17:58 CET
Market cap
38.98 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-92.48 USD m
Free cash flow, TTM
-47.00 USD m
EPS diluted, TTM
-125.60
P/E
-
Compare

Price

IRLA against its 20, 50 and 200-day averages
2050200beatmiss
Patternshover a marker to name it
Sales mean, own scalesmoothed
RS 2Sales 0.00Price0.000.00100.00200.00300.00590K1.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IRLAclose 39.9520-day 33.9050-day 31.40200-day 27.1239.9552w low

95.6% under the 52-week high of 909.98 on 12 Dec 2025. 52-week low 15.10 on 1 Jul 2026. Last 15 sessions, 66.5% high to low. This session is unfinished.

Volume 2.64× normal · the line is the 50-bar volume average

Setup. RS line 2
CANSLIM 2 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Average Volume: Over 200K — not on the tape: EPS Growth This Year: High (>25%)
VCP 2 of 6 — fails: 52-Week High/Low: 0-10% below High; Average True Range: Under 2; RSI (14): Not Overbought (<60); Relative Volume: Under 1
Minervini 2 of 4 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 4 of 5 — fails: 20-Day High/Low: 0-5% below High
Leaders 2 of 5 — fails: Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 3 of 4 — fails: 52-Week High/Low: New High
Growth 1 of 4 — fails: Return on Equity: Over +15% — not on the tape: EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%)
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 1 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15; P/B: Under 2
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; Performance: Year +50% — not on the tape: Float: Under 100M
Accumulation 2 of 4 — fails: Institutional Transactions: Over +10%; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; Average Volume: Over 500K

Profile

IRLA
52-week range, 3% of the way up
15.10909.98

IRulya Therapeutics, Inc. is a biopharmaceutical company, which engages in unlocking the power of a patient's biology for the treatment of rare diseases. Its product includes eDSP, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Employees38
IPOMay 09, 2019
Beta1.78
ATR, 14d4.39
Rel volume2.64
Insider own6.34%
Inst own124.15%

Snapshot

6 groups

Valuation

Index-
Market Cap433.11M
Enterprise Value460.94M
Income-92.48M
Sales0.00M
Book/sh-34.73
Cash/sh10.70
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees38
IPOMay 09, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C3.73
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio14.52
Current Ratio14.52
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-125.60
EPS next Y-9.20
EPS next Q-1.39
EPS this Y-
EPS next Y-
EPS next 5Y74.07%
EPS past 3/5Y-2.82% 8.64%
Sales past 3/5Y- -
EPS Y/Y TTM43.02%
Sales Y/Y TTM-
EPS Q/Q82.10%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.56.07% -

Ownership

Insider Own6.34%
Insider Trans0.00%
Inst Own124.15%
Inst Trans-0.43%
ROA-76.68%
ROE-153.84%
ROIC-85.24%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2017.83%
SMA5027.22%
SMA20047.32%
Trades-

Technical

Shs Outstand1.02M
Shs Float-
Short Float-
Short Ratio2.53
Short Interest0.13M
52W High909.98 -95.61%
52W Low15.10 164.57%
Volatility16.24% 13.92%
ATR (14)4.39
RSI (14)64.11
Beta1.78
Rel Volume2.64
Avg Volume50.46K
Volume54,733

Performance

Perf Week36.30%
Perf Month33.17%
Perf Quarter17.36%
Perf Half Y69.28%
Perf YTD-94.04%
Perf Year-88.32%
Perf 3Y-77.84%
Perf 5Y-98.60%
Perf 10Y-
Recom1.11
Target Price74.44
Prev Close38.33
Price39.95
Change %4.23%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Oct 09, 2026InitiatedRRaymond JamesOutperform$72+80.2%
Sep 24, 2026InitiatedRRodman & RenshawBuy$70+75.2%
Sep 22, 2026UpgradeCCitizensMkt Perform → Mkt Outperform$77+92.7%
Aug 20, 2026InitiatedCCraig HallumBuy$68+70.2%
Jul 29, 2026InitiatedOOppenheimerOutperform$82+105.3%
Jun 24, 2026InitiatedLLeerink PartnersOutperform$4-90.0%
Jun 23, 2026InitiatedCCantor FitzgeraldOverweight$4-90.0%
Jan 30, 2026DowngradeCCitizens JMPMkt Outperform → Mkt Perform
Aug 05, 2025InitiatedCCitizens JMPMkt Outperform$9-77.5%
Mar 24, 2025InitiatedOOppenheimerOutperform$10-75.0%

Peers

Mkt cap
TickerCompanyMkt cap
GOSSGossamer Bio Inc74.64M
INSMInsmed Inc26.13B
LQDALiquidia Corp5.21B
TENXTenax Therapeutics Inc75.69M
MNKDMannkind Corp1.34B
SVRASavara Inc1.07B
UTHRUnited Therapeutics Corp25.38B
TECXTectonic Therapeutic Inc429.78M
SNDXSyndax Pharmaceuticals Inc890.38M
TRVITrevi Therapeutics Inc2.00B

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Blue Devil TrustFormer Board MemberOct 09 '26Proposed Sale29.833,471103,534Nov 05 03:42 PM
Dirk ThyeOfficerOct 21 '26Proposed Sale36.033,700133,329Oct 21 05:15 PM
LUCA BENATTIOFFICERDec 26 '25Proposed Sale3.4650,000173,211Dec 29 05:51 PM
Benatti LucaDirectorDec 26 '25Sale3.4750,000173,50039,179Dec 29 05:36 PM
Hannah BrendanCBO, COO & CCODec 05 '25Option Exercise0.9127,55125,012361,827Dec 08 08:12 AM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.79B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-12.310-28.020-12.3100.000.003
2026Q12026-05-1975.040-26.00078.1520.000.001
2025Q42026-03-03-28.000-35.940-141.620.000.005
2025Q32025-11-12-50.000-43.000-49.8300.000.006
2025Q22025-08-11-68.000-50.340-68.7520.000.006
2025Q12025-05-13-68.000-45.500-68.4100.000.004
2024Q42025-03-24-56.000-36.000-56.7760.000.005
2024Q32024-11-13-26.000-34.660-25.4480.000.003
2024Q22024-08-13-129.34--128.680.00--
2021Q32022-10-28-145.92--145.840.00-5
2022Q22022-08-09-102-56.060-102.040.000.001
2022Q12022-05-10-144-109.52-143.630.000.005
2021Q42022-03-07-146.66-129.9-156.240.000.006
2021Q22021-08-09-148-158.94-147.050.000.007
2021Q12021-05-10-156-139.44-156.220.000.00-
2020Q42021-03-01-138-146.44-139.150.000.007

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-116--92.9620.00-
2019FY-388-413.3-388.610.000.00
2020FY-526.26-533.38-526.790.000.00
2021FY-606-588.1-605.310.000.00
2024FY-262-243.2-2620.000.00
2025FY-202-218.84-335.270.000.00
2026FY--52.000--0.00
2027FY--16.000--0.00
2028FY--16.000---
2029FY--16.000---
2030FY--16.000---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-086000.000.000.00
2026Q3S2026-09-215000.000.000.00
2026Q3S2026-08-194000.000.000.00
2026Q3S2026-08-143000.000.000.00
2026Q3S2026-07-283000.000.000.00
2026Q3S2026-06-232000.000.000.00
2026Q3S2026-06-221000.000.000.00
2026Q3S2026-05-101000.000.000.00
2026Q3S2026-05-082000.000.000.00
2026Q3S2026-05-053000.000.000.00
2026Q3S2026-03-034000.000.000.00
2026Q3S2026-01-304000.000.000.00
2026Q3S2025-11-133000.000.000.00
2026Q3S2025-11-123000.000.000.00

Estimate history

EPS, annual-91.166-92.962-388.61-526.792-605.314-308.45-168.568-262.714-335.266-125.6028
Period201720182019202020212022202320242025TTM
EPS, quarterly-128.684-25.448-56.776-68.41-68.752-49.83-141.61678.152-12.309
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.1340.1340.1340.1480.150.1810.2150.220.2791.017
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.2160.2160.220.220.2680.2720.2790.691.017
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.150.140.190.320.170.340.330.190.05
Gross Profit-0.15-0.14-0.19-0.32-0.17-0.34-0.33-0.19-0.05
Selling, General and Administrative Excl. Other60.6550.2935.9824.3249.9189.9778.5638.9812.07
Research and Development32.9935.3818.599.2525.1860.8061.3130.2110.09
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-60.80-50.43-36.17-24.64-50.09-90.32-78.89-39.17-12.12
Interest Expense-----0.000.000.000.96
Unusual Expense38.8932.0722.8210.382.060.000.000.000.21
Net Income Before Taxes-94.64-80.77-56.74-31.58-51.94-89.94-76.85-36.98-12.48
Income Taxes-2.163.210.09-0.20-0.280.000.000.000.00
Consolidated Net Income-92.48-83.98-56.83-31.39-51.66-89.94-76.85-36.98-12.48
Net Income From Continuing Operations-92.48-83.98-56.83-31.39-51.66-89.94-76.85-36.98-12.48
Net Income-92.48-83.98-56.83-31.39-51.66-89.94-76.85-36.98-12.48
EPS (Recurring)-10.64-245.66-188.85-129.54-299.84-605.31-526.79-388.61-91.89
EPS (Basic, Before Extraordinaries)-125.00-335.27-262.71-168.57-308.45-605.31-526.79-388.61-92.96
EPS (Diluted)-125.60-335.27-262.71-168.57-308.45-605.31-526.79-388.61-92.96
EBITDA-60.65-50.29-35.98-24.32-49.91-89.97-78.56-38.98-12.07
Non-Operating Income (Expense)5.051.732.253.440.210.372.042.190.81
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense12.504.033.754.1213.1329.8514.472.06-
Shares Outstanding1.020.280.220.210.180.150.150.130.13
Market Capitalization38.9838.9882.2838.1623.03379.54820.711,508.451,506.59

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.040.040.040.040.040.030.020.09
Gross Profit-0.04-0.04-0.04-0.04-0.04-0.03-0.02-0.09
Selling, General and Administrative Excl. Other22.0511.0816.2011.339.8612.9010.098.46
Research and Development5.466.8412.608.086.558.145.834.92
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-22.09-11.11-16.24-11.36-9.89-12.93-10.11-8.55
Unusual Expense55.37-39.8120.962.376.372.372.36-2.23
Net Income Before Taxes-75.4130.57-36.31-13.49-15.98-14.98-12.45-5.48
Income Taxes0.07-5.343.15-0.050.070.050.010.01
Consolidated Net Income-75.4935.91-39.46-13.44-16.05-15.03-12.46-5.49
Net Income From Continuing Operations-75.4935.91-39.46-13.44-16.05-15.03-12.46-5.49
Net Income-75.4935.91-39.46-13.44-16.05-15.03-12.46-5.49
EPS (Recurring)-5.9917.51-88.95-43.69-49.65-60.86-49.25-32.69
EPS (Basic, Before Extraordinaries)-12.3178.75-141.62-49.83-68.75-68.41-56.78-25.45
EPS (Diluted)-12.3178.15-141.62-49.83-68.75-68.41-56.78-25.45
EBITDA-22.05-11.08-16.20-11.33-9.86-12.90-10.09-8.46
Non-Operating Income (Expense)2.041.880.890.240.280.320.020.83
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.551.020.940.991.011.090.890.89
Shares Outstanding1.020.690.280.270.270.220.220.22
Market Capitalization38.9813.98186.6888.8388.4858.6482.2833.59

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments17.7540.7875.0690.18106.80133.8299.8671.727.39
Short Term Receivables3.620.880.990.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.522.371.393.574.874.046.190.830.14
Total Current Assets22.9044.0477.4493.75111.67137.86106.0672.557.54
Net Property, Plant & Equipment1.050.810.620.681.431.101.330.280.12
Total Investments and Advances0.080.080.083.5819.9350.4616.760.000.00
Intangible Assets67.8260.0581.305.90-----
Deferred Tax Assets0.1111.6812.301.03-----
Other Assets1.689.518.470.000.190.040.220.040.06
Total Assets93.63126.15180.20104.94133.23189.47124.3772.887.72
Short Term Debt Incl. Current Port. of LT Debt18.140.100.060.450.740.240.000.000.00
Accounts Payable2.222.902.030.574.913.560.000.490.52
Other Current Liabilities22.864.287.472.058.5713.208.890.961.25
Total Current Liabilities43.237.289.573.0714.2217.008.891.461.76
Long Term Debt0.3314.7113.750.000.420.210.000.007.17
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.1116.6417.611.28-----
Other Liabilities85.6857.3854.190.000.000.000.000.001.89
Total Liabilities129.3596.0195.124.3514.6417.208.891.4610.82
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00104.0517.18
Common Equity-35.7130.1585.08100.59118.59172.26115.48-32.63-20.28
Total Shareholders Equity-35.7130.1585.08100.59118.59172.26115.4871.42-3.10
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-35.7130.1585.08100.59118.59172.26115.4871.42-3.10
Total Liabilities & Stockholders Equity93.63126.15180.20104.94133.23189.47124.3772.887.72
Book Value Per Share-128.18137.02395.99556.74788.621,166.17859.55-243.10-151.11
Tangible Book Value Per Share-371.58-135.9017.62524.09788.621,166.17859.55-243.10-151.11
Full-Time Employees3836322155372319-
Price to Book Ratio-1.102.730.460.223.204.7613.0611.84-
Return on Assets-76.42-37.10-22.01-43.38-55.75-48.97-37.50-30.96-
Return on Equity--98.63-33.81-47.14-61.85-53.42-39.57-36.52-
Return on Invested Capital--126.68-31.76-51.36-75.58-44.56-32.02-17.47-300.69
Quick Ratio0.536.058.0930.557.858.1111.9349.794.28
Current Ratio0.536.058.0930.557.858.1111.9349.794.28

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-92.48-83.98-56.83-31.39-51.66-89.94-76.85-36.98-12.48
Depreciation0.150.140.190.320.170.340.330.190.05
Other Funds (Non Cash)47.6634.5325.2211.0417.5630.9315.471.611.12
Funds from Operations-49.62-54.27-31.42-20.27-34.21-58.67-61.05-35.18-11.30
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital2.7012.84-0.481.98-9.83-4.2610.231.90-0.39
Cash from Operating Activities-46.92-41.42-31.90-18.29-44.04-62.93-50.82-33.28-11.70
Capital Expenditures-0.08-0.35-0.26-0.16-0.13-0.18-0.05-0.06-0.21
Net Assets From Acquisitions8.000.000.00-2.120.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.0910.660.000.000.00-
Purchase or Sale of Investments18.3723.5822.16-2.577.4759.13-52.38-17.69-46.54
Purchase of Investments-20.63-34.42-89.56-113.78-75.02-38.79-187.14-135.41-55.24
Sale Or Maturity of Investments39.0058.00111.73111.2182.4997.92134.76117.728.70
Other Uses0.000.000.00-1.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities26.2923.2321.91-5.7618.0058.95-52.43-17.75-46.75
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock127.3917.910.230.150.766.81118.9177.9275.68
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock127.3917.910.230.150.766.81118.9177.9275.68
Proceedsfrom Stock Options138.7817.690.000.000.610.00117.6377.8375.65
Issuance or Reduction of Debt, Net-5.540.000.00-0.010.000.000.000.000.25
Change in Long Term Debt0.000.000.00-0.010.000.000.000.000.25
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.25
Reduction of Long Term Debt0.000.000.00-0.010.000.000.000.000.00
Net Financing Active Other Cash Flow-0.060.00-5.000.000.000.000.000.000.00
Other Financing Activities Uses-0.060.00-5.000.000.000.000.000.000.00
Cash from Financing Activities121.7917.91-4.780.140.716.81118.8877.3775.93
Exchange Rate Effect-2.00-0.110.230.080.180.06---
Net Change in Cash99.16-0.40-14.54-23.83-25.142.8815.6326.3417.48
Free Cash Flow-47.00-41.78-32.16-18.45-44.17-63.11-50.87-33.33-11.91
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit--4.960.00-0.25-0.280.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments115.9818.1617.7526.2934.7131.60
Short Term Receivables4.775.273.620.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.662.141.522.912.642.23
Total Current Assets123.4125.5822.9029.2037.3433.83
Net Property, Plant & Equipment0.510.961.051.101.080.94
Total Investments and Advances0.080.080.080.080.080.08
Intangible Assets0.000.0067.8267.7367.5762.37
Deferred Tax Assets--0.11---
Other Assets0.000.001.6811.8011.149.88
Total Assets124.0026.6293.63109.90117.21107.09
Short Term Debt Incl. Current Port. of LT Debt0.000.1118.1417.630.110.10
Accounts Payable4.645.392.223.401.763.01
Other Current Liabilities3.863.2622.865.015.605.25
Total Current Liabilities8.508.7743.2326.047.478.36
Long Term Debt0.000.290.330.3617.3815.65
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.115.595.595.17
Other Liabilities7.011.8985.6876.8475.0459.33
Total Liabilities15.5110.95129.35108.84105.4788.51
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value143.810.000.000.000.000.00
Common Equity-35.3215.67-35.711.0611.7418.58
Total Shareholders Equity108.4915.67-35.711.0611.7418.58
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity108.4915.67-35.711.0611.7418.58
Total Liabilities & Stockholders Equity124.0026.6293.63109.90117.21107.09
Book Value Per Share-34.7322.73-128.183.8943.7784.29
Tangible Book Value Per Share-34.7322.73-371.58-244.67-208.23-198.62
Full-Time Employees--38---
Price to Book Ratio-1.100.89-5.2383.887.543.16
Return on Assets-76.68-49.42-76.42-48.20-38.91-45.58
Return on Equity-153.84-192.90--247.78-167.04-130.90
Return on Invested Capital-69.58224.94--947.95-55.13-43.91
Quick Ratio14.522.920.531.125.004.05
Current Ratio14.522.920.531.125.004.05

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-75.4935.91-39.46-13.44-16.05-15.03
Depreciation0.040.040.040.040.040.03
Other Funds (Non Cash)64.14-41.2021.433.286.473.35
Funds from Operations-11.30-5.25-22.95-10.12-9.54-11.65
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-7.58-2.3812.470.19-1.872.05
Cash from Operating Activities-18.89-7.63-10.48-9.93-11.41-9.60
Capital Expenditures0.000.00-0.00-0.07-0.13-0.15
Net Assets From Acquisitions8.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.0012.008.07-1.716.1711.05
Purchase of Investments0.000.00-4.92-15.71-11.84-1.95
Sale Or Maturity of Investments0.0012.0013.0014.0018.0013.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities8.0012.008.07-1.786.0410.90
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock108.9914.992.031.3814.410.09
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock108.9914.992.031.3814.410.09
Proceedsfrom Stock Options108.9914.9913.421.382.890.00
Issuance or Reduction of Debt, Net0.00-5.540.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.060.000.000.000.000.00
Other Financing Activities Uses-0.060.000.000.000.000.00
Cash from Financing Activities108.939.442.031.3814.410.09
Exchange Rate Effect-0.23-1.46-0.27-0.040.020.17
Net Change in Cash97.8212.35-0.64-10.379.051.56
Free Cash Flow-18.89-7.63-10.48-10.00-11.54-9.75

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.45%0.1M1.0M43.29K
2026-10-1516.29%0.2M1.0M30.48K
2026-09-306.12%0.1M1.0M29.57K
2026-09-155.13%0.1M1.0M29.84K
2026-08-315.82%0.1M1.0M31.96K
2026-08-146.15%0.1M1.0M55.58K
2026-07-315.78%0.1M1.0M56.22K
2026-07-155.38%0.1M0.9M64.62K
2026-06-3012.00%0.1M0.9M228.88K
2026-06-1512.92%0.1M0.8M246.38K
2026-05-2913.22%0.1M0.8M283.11K
2026-05-1511.28%0.1M0.8M294.18K
2026-04-3012.61%0.1M0.7M523.31K
2026-04-1513.79%0.1M0.7M522.58K
2026-03-3128.60%0.1M0.2M346.90K
2026-03-1323.07%0.1M0.2M320.23K
2026-02-2717.17%0.0M0.2M277.41K
2026-02-1321.39%0.1M0.2M240.05K
2026-01-303.88%0.0M0.2M9.23K
2026-01-157.15%0.0M0.2M3.75K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-21144Filing for proposed sale of securities under Rule 144.SEC
2026-10-193Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-193Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-193Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-193Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-193Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-193Initial statement of beneficial ownership of securities2026-10-08SEC
2026-10-198-KCurrent report2026-10-19SEC
2026-10-14SCHEDULE 13GSEC
2026-10-14SCHEDULE 13GSEC
2026-10-098-KCurrent report2026-10-07SEC
2026-10-08S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-10-068-KCurrent report2026-10-06SEC
2026-10-02DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-028-KCurrent report2026-09-30SEC
2026-09-148-KCurrent report2026-09-08SEC
2026-09-048-KCurrent report2026-08-31SEC
2026-08-278-KCurrent report2026-08-23SEC
2026-08-25DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-06SEC
2026-08-24EFFECTEffectiveness filing by commission orderSEC
2026-08-178-KCurrent report2026-08-17SEC
2026-08-14SCHEDULE 13GSEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-05S-3/ASEC
2026-08-04SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-1200173.50K1
2025-110000

Institutional holders

Manager% owned
Ikarian Capital, LLC7.10%
MILLENNIUM MANAGEMENT LLC6.96%
BALYASNY ASSET MANAGEMENT L.P.6.88%
Squadron Capital Management LLC3.97%
Shay Capital LLC1.72%
BOOTHBAY FUND MANAGEMENT, LLC1.37%
JANE STREET GROUP, LLC1.24%
VANGUARD CAPITAL MANAGEMENT LLC1.18%
GEODE CAPITAL MANAGEMENT, LLC0.96%
MORGAN STANLEY0.40%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND1.18%
Fidelity Extended Market Index Fund0.53%
Fidelity Series Total Market Index Fund0.12%
Fidelity Total Market Index Fund0.11%
Victory Extended Market Index Fund0.08%
Fidelity Nasdaq Composite Index Fund0.06%
Guggenheim Active Allocation Fund0.00%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. IRLA. Cached 15 minutes.